Search

Potassium acetate

Potassium sulfate

Phosphoric acid

Phosphoric Acid is a colorless, odorless phosphorus-containing inorganic acid. Phosphoric acid is a sequestering agent which binds many divalent cations, including Fe++, Cu++, Ca++, and Mg++.

Phylloquinone

[L33319] Phylloquinone has been synthesized since at least 1939,[A234384] and was approved by the FDA prior to 1955.[L33389]

Damoctocog alfa pegol

[L4576,A38909] This product has been engineered by Bayer[L4576] and a biological license application has been filed with the FDA in August 2017 and FDA approved in August 2018.[F1609] … In order to extend half-lives, techniques such as fusion to protein conjugates (Fc part of IgG1 or albumin), chemical modification (PEGylation), and protein sequence modification have been utilized.

Agalsidase beta

[A220343] Agalsidase beta was granted FDA approval on 24 April 2003.[L16383] … [A220228,A220233] Use of agalsidase beta has decreased in Europe, in favor of agalsidase alfa, after a contamination event in 2009.

Crotalus scutulatus antivenin

Crotalus scutulatus antivenin is derived and purified immunoglobulin fragments obtained from other domestic animals such as sheep previously immunized with Crotalus scutulatus (also known as the _Mojave … Since it was approved by the Food and Drug Administration in October 2000, crotalidae poyvalent immune Fab (CroFab) has largely replaced previously used crotaline antivenom.

Dordaviprone

[L53833] Dordaviprone was initially studied as an anticancer agent that induces TNF-Related Apoptosis-Inducing Ligand (TRAIL). … On August 6, 2025, dordaviprone was granted accelerated approval by the FDA.[L53838] It is used to treat patients with diffuse midline glioma harboring an H3 K27M mutation.

Autologous cultured chondrocytes

It has been used since 1995 as Carticel and gained biologic license in 1997. The surgical implantation was first performed in Sweden. … It serves as an alternative repair treatment for patients with inadequate response to pre-existing surgical methods.

Lymecycline

It is marketed by Galderma and used in the UK as well as New Zealand in addition to other countries. … [L13880,L13883] It has been proven a cost-effective alternative to treatment with [minocycline] with comparable safety and efficacy.[A203255] Lymecycline was initially discovered in 1961.